These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29087803)

  • 1. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of mTOR inhibitors in adult solid organ transplantation.
    Ventura-Aguiar P; Campistol JM; Diekmann F
    Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitors in pediatric liver transplant recipients.
    Dumortier J; Couchonnal E; Lacaille F; Rivet C; Debray D; Boillot O; Lachaux A; Ackermann O; Gonzales E; Wildhaber BE; Jacquemin E; McLin V
    Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
    Caletti C; Granata S; Tomei P; Lupo A; Zaza G
    G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteinuria associated with mTOR inhibitors after kidney transplant.
    Guney M; Sahin G; Yilmaz B; Canbakan M; Gucun M; Kayatas K; Eren P; Titiz I
    Exp Clin Transplant; 2014 Dec; 12(6):539-42. PubMed ID: 25489805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
    Opelz G; Unterrainer C; Süsal C; Döhler B
    Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.
    Pengel LH; Liu LQ; Morris PJ
    Transpl Int; 2011 Dec; 24(12):1216-30. PubMed ID: 21955006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to mTOR-inhibitors with calcineurin inhibitor elimination or minimization reduces urinary polyomavirus BK load in kidney transplant recipients.
    Yen CL; Tian YC; Wu HH; Weng CH; Chen YC; Tu KH; Liu SH; Lee CC; Lai PC; Fang JT; Hung CC; Yang CW; Li YJ
    J Formos Med Assoc; 2016 Jul; 115(7):539-46. PubMed ID: 26994751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibitors for management of encapsulating peritoneal sclerosis: a review of literatures.
    Ghadimi M; Dashti-Khavidaki S; Khalili H
    Ren Fail; 2016 Nov; 38(10):1574-1580. PubMed ID: 27425661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
    Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
    Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.
    de Paula MI; Medina Pestana JO; Nicolau Ferreira A; Pontello Cristelli M; Fabiano Franco M; Aguiar WF; Tedesco-Silva H; Rosso Felipe C
    Ther Drug Monit; 2016 Feb; 38(1):22-31. PubMed ID: 26121616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.